Navigation Links
Phase III data show investigational compound empagliflozin significantly reduced blood glucose in adults with type 2 diabetes
Date:6/22/2013

RIDGEFIELD, Conn. and INDIANAPOLIS, June 22, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced two late-breaking presentations with results from a pooled analysis of four pivotal phase III trials of the investigational agent empagliflozin* in people with type 2 diabetes (T2D).

In the pooled analysis, presented at the American Diabetes Association 73rd Scientific Sessions®, people with T2D treated with empagliflozin versus placebo achieved significant reductions in HbA1c, fasting plasma glucose (FPG), weight and blood pressure after 24 weeks.1 In the same analysis, people treated with empagliflozin vs. placebo experienced an increased frequency of genital infections, but not urinary tract infections (UTIs).2

Empagliflozin is a member of the sodium glucose co-transporter-2 (SGLT2) inhibitor class of compounds, and is being investigated for the reduction of blood glucose levels in adults with T2D. The emerging SGLT2 inhibitor class removes excess glucose through the urine by blocking glucose re-absorption by the kidney.

"We are primarily encouraged by the blood sugar lowering results seen in this analysis," said Christophe Arbet-Engels, PhD, vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "People with type 2 diabetes face different challenges. Many of them are not meeting their blood sugar level goals and have difficulties managing other factors such as weight and increased blood pressure."

About Posters #69-LB and #74-LB
Both posters are based on pooled data from 2,477 people with T2D who participated in one of four randomized, placebo-controlled phase III trials that investigated empagl
'/>"/>

SOURCE Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Follow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541
2. Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulfonylurea in adults with type 2 diabetes
3. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
4. Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
5. Safinamide Phase III Study Results Presented at 2013 MDS Meeting
6. Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinsons Disease
7. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
8. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
9. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
10. Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma
11. Lilly Voluntarily Terminates Phase II Study for LY2886721, a Beta Secretase Inhibitor, Being Investigated as a Treatment for Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Quebec , Jan. 15, 2014  Valeant Pharmaceuticals International, ... announced that the applicable waiting period under the Hart-Scott-Rodino ... the previously announced tender offer by its indirect wholly-owned ... outstanding shares of common stock of Solta Medical, Inc. ...
(Date:1/15/2014)... 2014  A novel wearable injector slightly larger than an Oreo ... to self-inject prescription drugs in the large doses required to ... autoimmune deficiencies, and genetic disorders.  An emerging ... 2018, according to analysts.   Many of these drugs will require ...
(Date:1/14/2014)... The Brandeis Medical Center, led by Dr. Emmanuel Brandeis , ... laser tattoo removal experience with the advanced Astanza Duality laser and ... quality cosmetic services with cutting edge medical technology and offering expert ... has seen a dramatic increase in the presence of ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... 2011 A new report in the March issue of ... beat brand names when it comes to safety, efficacy, and ... drug programs offering these drugs at prices as low as ... Walgreens, and Walmart have been steadily expanding their discount programs, ...
... JumpStart Ventures , the non-profit that invests in ... Ohio, and Cleveland Clinic , announced a ... Inc. The Cleveland-based company is developing a topical ... formation in wounds. (Logo: http://photos.prnewswire.com/prnh/20060209/CLJUMPSTARTLOGO) ...
Cached Medicine Technology:Consumer Reports Health: Best Drugs for What Ails You, Plus Where to Buy Them for $4 a Month 2Consumer Reports Health: Best Drugs for What Ails You, Plus Where to Buy Them for $4 a Month 3Consumer Reports Health: Best Drugs for What Ails You, Plus Where to Buy Them for $4 a Month 4JumpStart Ventures and Cleveland Clinic Invest in SironRX Therapeutics 2JumpStart Ventures and Cleveland Clinic Invest in SironRX Therapeutics 3JumpStart Ventures and Cleveland Clinic Invest in SironRX Therapeutics 4
(Date:7/9/2014)... researchers have uncovered mutations in a cell-signaling pathway that ... may expand treatments for patients because drugs targeting some ... in clinical trials. , Reporting July 9 in ... including researchers at Washington University School of Medicine in ... tumors from 230 patients with lung adenocarcinoma. , "This ...
(Date:7/9/2014)... a relatively optimistic picture of women,s chances of surviving ... the chest wall or skin, but not beyond. ... size and whether they have involved lymph nodes, are ... advanced" tumors, suggesting that they are a relatively serious ... breast cancers of this and other types account for ...
(Date:7/9/2014)... drug users in Russia might contribute to HIV ... conducted by researchers from Boston University Schools of ... Petersburg Pavlov State University, sought to discover the ... of a cohort of HIV-positive people with lifetime ... arrested by police were more likely to share ...
(Date:7/9/2014)... personal and subjective, the human brain turns them ... across different senses, situations and even people, reports ... Anderson. , "We discovered that fine-grained patterns of ... of the brain associated with emotional processing, act ... subjective feeling," says Anderson, associate professor of human ...
(Date:7/9/2014)... There has been a sharp increase in the number ... MyChart, the online, interactive service that allows patients to ... providers, schedule appointments, and renew prescriptions. , Over a ... MyChart each year increased five-fold, while the number ... according to a study by Dr. David Gerber ...
Breaking Medicine News(10 mins):Health News:Lung cancer study hints at new treatments 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:BU researchers relate arrests with HIV risk environment 2Health News:Study cracks how the brain processes emotions 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3
... DavisPTnetwork™, a new social networking Web site, at the APTA ... online physical therapy continuing education courses (contact hours and CEUs), ... ... Philadelphia, PA (PRWEB) March 23, 2009 -- F.A. Davis is ...
... Digital,s unique PC Network software with the advanced SharkNet Duplicator series ... a given network onto a duplicator. , ... Los ... the availability of their latest innovation; the network connectable standalone duplicator ...
... Tuberculosis Day HARRISBURG, Pa., March 23 State Health ... public awareness of tuberculosis, or TB, and the importance ... disease. "In 2008, we saw an increase in the ... more cases resistant to medication, which makes the disease ...
... Nickolas Hooks of Charleston, SC, will travel ... 31, 2009 to meet with congressional leaders and gain ... research toward a cure for epilepsy.Hooks, 15, is one ... in Kids Speak Up! , a national program ...
... In light of the recent recall of eggs ... safety expert Jeff Nelken is strongly advising Americans, especially ... take precautions when eating eggs at home or in ... potentially one of the most dangerous foods in terms ...
... PEMBROKE, Bermuda, March 23 Darwin National,Assurance Company, ... Ltd (NYSE: AWH ), today announced ... moderate a panel at the PLUS Medical,Symposium held ... The panel, titled "Do,You Know Where Your Tissue/Organ/Medical ...
Cached Medicine News:Health News:New Online Network Features Continuing Education Courses for Physical Therapists 2Health News:Vinpower Digital Introduces the Industry's First Standalone Networkable Duplication Tower 2Health News:Vinpower Digital Introduces the Industry's First Standalone Networkable Duplication Tower 3Health News:Pennsylvania Sees Increase in Tuberculosis, Emphasizing Need for Awareness 2Health News:South Carolina Youth Shares Epilepsy Message on Capitol Hill 2Health News:Food Safety Expert Offers Tips to Be Safe in Wake of Costco & Safeway Egg Recall 2Health News:Darwin to Moderate Panel at Plus Medical Symposium 2Health News:Darwin to Moderate Panel at Plus Medical Symposium 3
... indoor positioning supports patient safety by ... the right patients are in the ... Respond to the exact patient location ... monitor alarms. Measure patient flow times ...
... are preominantly used for routine blood collection. ... of the needle protective cap simplifies visual ... example, yellow symbolises the needle dimension 20 ... mm) and black 22 G (0.70 mm). ...
DiaMed-ID Micro Typing System...
Bio-Rad's ScanGel® cards for ABO reverse grouping, antibody screening and crossmatching include - ScanGel Neutral, ScanGel Coombs, Anti-IgG, -C3d (AHG), ScanGel Coombs + Neutral, ScanGel Anti-Ig...
Medicine Products: